Business
China Surpasses Musk, Launches First Commercial Brain Chip
China’s NEO, a brain-computer interface developed at Tsinghua University, surpasses Neuralink by being the first commercially approved brain chip after clinical trials, aimed to aid neurological disorders.
Key Points
-
China has approved the first commercially available brain chip, NEO, designed for spinal cord injury and paralysis patients. Developed by Tsinghua University and Neuracle Technology, NEO sits between the skull and brain, minimizing invasiveness. It has cleared clinical testing and will enter mass production for China’s healthcare system.
-
Neuralink, led by Elon Musk, lags in regulatory approval for its BCI technology in the US. Musk highlights its potential for tetraplegia and vision restoration, calling it "Jesus-level technology." The implants could enable digital communication and device control via thoughts, with exciting prospects but early-stage challenges.
- Experts highlight privacy and cybersecurity concerns with BCIs, cautioning about potential risks like hacking and manipulation. Despite being promising neuroscience advancements, brain implants face biological challenges. Neuralink’s trials reveal significant impacts, as patients like Audrey Crews work to refine and advance the technology.
China has taken the lead over Elon Musk’s Neuralink in the commercialization of brain-computer interface (BCI) technology with the launch of NEO, the world’s first commercially approved brain chip. Developed by Tsinghua University and Neuracle Technology, the coin-sized NEO implant is designed for individuals with spinal cord injuries and paralysis, offering potential control over parts of the nervous system. The device, which has successfully cleared clinical trials, will be mass-produced for China’s healthcare system.
The NEO implant differentiates itself from Neuralink’s N1 device by its less invasive approach. Unlike the N1, which penetrates the cerebral cortex, NEO sits between the skull and the brain, using eight sensors placed against the dura mater, minimizing procedural invasiveness and associated risks. With 36 patients already testing the device successfully, experts anticipate its application may extend beyond paralysis to address conditions like Parkinson’s disease, epilepsy, stroke, and depression.
While both technologies share a vision of transforming human-machine interaction, Musk has emphasized Neuralink’s role in restoring capabilities such as movement and sight, describing them as “Jesus-level technologies.” Neuralink’s advancements include enabling users to perform tasks like typing or operating devices through thought alone, a vision that supporters believe could revolutionize digital communication.
Despite the promising prospects, concerns about privacy, security, and potential hacking risks accompany these innovations. Cybersecurity experts highlight the vulnerabilities these devices may present, such as unauthorized access to neural data or impairment of cognitive functions. While these concerns underscore the need for caution, the field’s rapid progress holds significant promise for improving the lives of those with neurological disorders.
In the US, Neuralink continues human trials with the N1 implant, testing it in nine individuals. One participant, Audrey Crews, has shared experiences of regaining previously lost capabilities, such as attempting to write after two decades, illustrating the technology’s potential impact while contributing to its further development.
